Aprepitant Oral Powder for Suspension
Brand names: Emend
Category: Gastroenterology
FDA status: To Be Discontinued · Last FDA update: Apr 8, 2026 · First posted: Apr 8, 2026 · 1 manufacturers, 1 listed presentations
As of Apr 8, 2026, the FDA lists Aprepitant Oral Powder for Suspension as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03) NDC 0006-3066-03 |
Merck Sharp & Dohme LLC | Not specified | To be discontinued in approximately early-September 2026. |
Related medications in shortage
Other Gastroenterology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Aprepitant Oral Powder for Suspension (FDA data as of Apr 8, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Aprepitant Oral Powder for Suspension. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/aprepitant-oral-powder-for-suspension.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).